Aman's Global Market Intelligence

Executive dashboard

S&P 500 · Fri cash close7,718.60−0.38%

Nasdaq Composite26,506.99−0.29%

Dow53,414.25−0.51%

Russell 20002,975.65+0.25%

VIX · Fri close14.53+1.47%

U.S. 2Y / 10Y · Fri official4.37% / 4.78%+3bp / +1bp

Dollar index · live indication99.08−0.08%

WTI / Gold futures$92.66 / $4,439.70+1.29% / −0.82%

Nikkei / Hang Seng · Sep. 766,399.79 / 25,440.94+2.12% / −0.82%

Shanghai Composite · Sep. 73,931.50+0.04%

Euro STOXX / DAX futures6,394 / 26,008−0.14% / −0.25%

ES / NQ futures7,719.50 / 29,642−0.03% / +0.26%

Cash closes cross-checked against Sep. 4 ETF/index marks; Monday indications use delayed TradingView scanner fields and CNBC's 02:23 EDT premarket page. Contract change is not the same as fair-value implied cash open. Official Treasury Sep. 4 par curve is 4.37%/4.78%. CNBC premarket · futures reference · Treasury XML

1 · Confirmed repricing

Oil up; escalation premium is real but contained so far

Front WTI was $92.66, +1.29%, after U.S. forces struck three Iranian crude carriers following missile attacks toward two Navy ships. The move confirms an energy premium, not the final geopolitical outcome. CNBC/CENTCOM account · WTI contract

2 · Split tape

Nikkei surges while Hong Kong and Dow futures lag

Nikkei +2.12% contrasts with Hang Seng −0.82%; NQ futures +0.26% contrasts with YM −0.43%. This is dispersion, not broad risk-on. European futures were modestly negative before cash open. CNBC world markets · CNBC futures

3 · Holiday/event stack

Labor Day → ORCL/ADBE → CPI → FOMC

U.S. cash is closed today. Oracle and Adobe are listed after Thursday's close, then CPI Friday and the FOMC/SEP Sep. 15–16. At 08:30 Italy, Friday's U.S. release is still six hours away. Nasdaq holidays · Nasdaq earnings · Fed

Market drivers

Macro, central banks, rates and geopolitics

Energy/inflation channel: WTI's +1.29% rise is the clearest overnight change. If sustained, it pressures consumers, transport margins and inflation expectations; a reversal below Friday's $91.48 area would weaken the shock thesis.
Rates remain restrictive: official 2Y/10Y closed 4.37%/4.78% after the hot August payroll report. Thin holiday indications near 4.374%/4.784% do not establish a new curve move. Treasury
Fed setup: Sep. 15–16 is verified on the official calendar. CPI comes first; market odds and political commentary can move, but only the committee statement is authoritative. Federal Reserve · BLS CPI schedule
Holiday caveat: Nasdaq lists Sep. 7 as Labor Day; a Tuesday U.S. gap can bypass technical entries and stops. schedule

Earnings, regulation, rotation and unusual moves

Cloud event risk: current Nasdaq records list ORCL and ADBE after-hours Sep. 10. Consensus EPS fields are third-party estimates—not management guidance. Nasdaq API
NVIDIA regulatory/M&A overhang: its Sep. 3 8-K says the definitive Hugging Face acquisition has an approximately $11.9B purchase price plus an employee retention program up to ~$1.0B, expected to close in 1H 2027 subject to approvals. Strategic platform upside is countered by integration and regulatory risk. SEC 8-K
Friday dispersion remains the latest U.S. evidence: VRT +4.35%, ORCL +3.08% and NVDA +0.84%; SNOW −5.41%, HPE −4.48% and ADBE −6.73%. Holiday futures cannot be mapped mechanically onto single stocks.
Verified capital events: Broadcom declared a $0.65 quarterly dividend payable Sep. 30 to Sep. 21 holders; IONQ public warrants cease NYSE trading before Sep. 29 and expire Sep. 30. Neither is fresh operating proof. AVGO 8-K · IONQ 8-K

Theme dashboards

AI · selective

Semis lead futures; energy and M&A raise the hurdle

Leaders/laggards: latest cash leaders VRT, ORCL, NVDA; laggards ADBE, SNOW and HPE. NQ +0.26% is supportive but non-executable for closed U.S. cash.
Evidence: NVIDIA previously reported Q2 revenue $46.7B and guided Q3 $54.0B ±2%; the new SEC-filed Hugging Face deal adds platform reach and approval/integration risk. NVIDIA results · deal filing
Valuation/speculation risk: 4.78% 10Y, oil/power costs, capex financing, export controls, concentration and high expectations. No refreshed company-wide EV multiple is asserted.

Quantum · highly speculative

No operating de-risking over the holiday

Latest cash: IONQ +1.28%, QUBT +0.63%, RGTI +0.13%, QBTS −1.43% Friday.
Primary check: SEC submissions through the cutoff show no newer IONQ operating filing after Aug. 28; that filing covers directors and warrant expiry. IONQ submissions
Risk: early revenue, uncertain architecture/unit economics, cash burn, dilution, long timelines, rates and extreme gaps. RGTI/VKTX-sized companies require small-cap discipline; no borrow availability or fee is claimed.

Peptide biotech · binary

Registry still has no posted results

Latest cash: VKTX +2.62%, LLY −0.88%, NVO −1.92% Friday.
Trial evidence: Lilly's NCT05929079 is completed Phase 3, randomized/double-masked, actual n=1,152; Week-80 body-weight change and AHI change are co-primary endpoints. The API says hasResults: false, so no efficacy statistic or safety conclusion is inferred. ClinicalTrials.gov
Corporate evidence/risk: Novo's Aug. 31 6-K reports continued share repurchases, not a clinical readout. Key risks remain endpoint/safety/tolerability, discontinuation, reimbursement, competition, manufacturing and regulation. NVO 6-K

Ranked ideas — conditional paper setups; fewer is better

1Conditional bullish

VRT · Vertiv (NYSE)

Exchange/risk class: NYSE, large-cap/high-beta AI power and cooling. Classification: confirmed momentum, no holiday entry. Applicable horizon: day and 1–4 weeks; 3–12+ months only after valuation/backlog/margin/FCF work. Direction: uncertain until Tuesday cash.

Thesis/catalyst/evidence: Friday's $280.53 (+4.35%) confirmed the pre-stated $270.99 breakout while Nasdaq fell; data-center electrical/cooling demand is structural. Counterargument: volume 3.32M was below its recent average, no new company catalyst was found, and oil/rates can compress the multiple.

Entry/confirmation: no gap chase; require $271.20 to hold and a close above $280.99 after Tuesday opens. Invalidation/downside: close below $268.83 cancels continuation; $254.50 is deeper support. Key risks: valuation, capex timing, execution, competition, energy/input costs, yields and gap-through stops. price reference

Thesis Confidence 82

Risk 92

Opportunity 54

2Conditional bullish

NVDA · NVIDIA (Nasdaq)

Exchange/risk class: Nasdaq, mega-cap semiconductor/high expectations. Classification: near-breakout with acquisition overhang. Applicable horizon: day and 1–4 weeks; 3–12+ months after margins, FCF, valuation and deal/regulatory review. Direction: uncertain until cash confirmation.

Thesis/catalyst/evidence: $230.36 (+0.84%) outperformed Nasdaq and reached $234.76; revenue/guidance momentum is verified. The Hugging Face deal could deepen developer distribution. Counterargument: it missed the $230.40 close trigger by $0.04; the deal costs ~$11.9B plus up to ~$1.0B retention and faces approvals.

Entry/confirmation: hold $229.63 and close above $234.76 with semiconductor breadth. Invalidation/downside: below $224.75 weakens; close below $220.41 invalidates. Key risks: margins, export controls, concentration, competition, M&A/integration, power, valuation and gaps. SEC deal filing · results

Thesis Confidence 86

Risk 92

Opportunity 53

1Avoid / failed hold

SNOW · Snowflake (NYSE)

Exchange/risk class: NYSE, large-cap cloud/extreme event, valuation and SBC risk. Classification: avoid—not an automatic short. Applicable horizon: day and 1–4 weeks only; no 3–12+ month bear case without FCF/SBC valuation work. Direction: uncertain; short loss can be unlimited.

Thesis/evidence: Friday's $337.18 (−5.41%) broke $350 and the $355.47 gap-hold level. Counterargument: product revenue +37%, RPO +30% and raised guidance support the business, creating squeeze/reversal risk. official release

Entry/confirmation: avoid; tactical bearish only after failed $350–356.83 reclaim and close below $337.11. Invalidation/downside: above $356.83 cancels bearish framing; prior long gap thesis fails below $319.25. Key risks: unlimited short loss, squeeze, growth upside, SBC, competition, valuation and gaps. Borrow/fees unknown.

Thesis Confidence 88

Risk 99

Opportunity 37

2Avoid / failed breakout

HPE · Hewlett Packard Enterprise (NYSE)

Exchange/risk class: NYSE, large-cap infrastructure/integration leverage. Classification: avoid until reclaim; no blind short. Applicable horizon: day and 1–4 weeks; 3–12+ months requires Juniper integration, margins, FCF/debt and valuation work. Direction: uncertain; short loss unlimited.

Thesis/evidence: $52.00 (−4.48%) closed below $52.48 and failed to clear $54.88. Counterargument: Q3 revenue was $12.2B (+34%), data-center networking +112.2%, and the FY27 framework calls for at least $5B FCF. SEC-furnished release

Entry/confirmation: avoid; bearish only after failed $52.48–54.64 reclaim and close below $51.49. Invalidation/downside: above $54.88 cancels bearish framing; below $49.80 confirms larger failure. Key risks: squeeze, integration, debt, server mix/margins, supply, competition and gaps. Borrow/fees unknown.

Thesis Confidence 87

Risk 97

Opportunity 36

Watchlist — maximum five

Name / exchange / risk	Classification & separately applicable horizon	Thesis, catalyst, evidence / counterargument	Entry / invalidation / key risks	C / R / O
Event watch ORCL · Oracle (NYSE) Mega-cap cloud; capex/debt/earnings gap	Pre-earnings momentum. Day/1–4w: applicable through Sep. 10. 3–12m: only after backlog, cloud growth, capex, FCF and valuation review. Direction uncertain.	$158.78 (+3.08%); after-hours Sep. 10 earnings verified. Counter: holiday macro risk; Nasdaq EPS consensus is not company guidance.	No pre-event chase; confirm >$159.70 or use post-report range. Below $154.04 weakens; below $146.92 invalidates. Risks: capex financing, execution, competition, rates/gap. calendar	83 / 97 / 46
Event watch ADBE · Adobe (Nasdaq) Large-cap software; earnings/transition	Damaged pre-event watch. Day/1–4w: only around Sep. 10. 3–12m: after AI monetization, growth, FCF/valuation and succession review. Direction uncertain.	$266.51 (−6.73%) on 6.64M volume; report date and Dec. 1 CEO transition verified. Counter: drop may pre-discount concerns; no new deterioration established.	Bullish only >$275.91; bearish only <$263.93 after failed reclaim. Above $292.88 invalidates bear; below $251.20 damages base. Risks: gap, competition, AI cannibalization. Adobe	84 / 98 / 41
Highly speculative IONQ · IonQ (NYSE) Quantum; extreme duration/dilution volatility	Reclaim watch. Day/1–4w: only above trigger. 3–12m: requires commercial/unit-economic proof. Direction uncertain.	$39.52 (+1.28%) missed $39.78 close; warrant dates verified. Counter: no operating de-risking; warrant event can distort flows.	Confirm close >$39.78, then $41.92. Below $38.83 weakens; below $36.78 invalidates. Risks: burn, dilution, architecture, timeline, rates/gaps. 8-K	84 / 100 / 37
Peptide NVO · Novo Nordisk ADR (NYSE) Large-cap pharma; ADR/pipeline/pricing	Range watch. Day/1–4w: only above $46.74/$48. 3–12m: after pipeline, reimbursement, manufacturing and valuation review. Direction uncertain.	$46.60 (−1.92%); share repurchase continues. Counter: buybacks are not clinical proof and competition remains intense.	Confirm >$46.74 then $48. Below $46.04 weakens; below $44.68 invalidates rebound. Risks: pricing, supply, efficacy/safety, competition, FX/ADR. 6-K	67 / 81 / 41
Small-cap biotech VKTX · Viking (Nasdaq) Small-cap peptide biotech; binary/financing	Momentum watch. Day/1–4w: technical only. 3–12m: requires trial, safety, cash-runway, regulatory and competition review. Direction uncertain.	$34.87 (+2.62%), near $34.95 high; no dated 7–30 day primary catalyst verified. Counter: below $36.26 20-day high; economics remain binary.	Confirm >$34.95 then $36.26. Below $33.56 weakens; below $31.70 invalidates. Risks: endpoints/statistics, safety, timing, cash runway/dilution, competition/manufacturing. SEC	60 / 98 / 38

C/R/O = Thesis Confidence / Risk / Opportunity, 0–100; higher Risk is riskier. Confidence measures evidence quality, never a guaranteed probability. Holiday gaps can bypass every level; no fill is assumed.

Changes versus the 2026-09-06 report

Risk shock now has market confirmation: WTI +1.29% at $92.66. Yesterday no liquid post-strike quote existed; today the premium is visible, though not disorderly.
Equities are mixed, not capitulating: ES −0.03% and NQ +0.26% contrast with YM −0.43%; Nikkei +2.12% contrasts with Hang Seng −0.82%. Regime stays risk-off watch rather than escalating to full risk-off.
European signal added: pre-open Euro STOXX 50/DAX futures were −0.14%/−0.25%; Friday cash indices remain stale and are not relabeled as Monday prices.
NVDA primary filing elevated: the Sep. 3 8-K verifies the ~$11.9B Hugging Face purchase price, up to ~$1.0B retention pool and 1H27 expected close subject to approvals; acquisition risk is now explicit in the idea.
No U.S. cash-trigger changes: Monday is Labor Day. VRT stays confirmed; NVDA remains a $0.04 close-rule miss; SNOW/HPE remain avoid-first; watchlist levels stay unchanged.
Peptide and quantum checks unchanged: Lilly trial results remain unposted; no newer IONQ operating filing was found. Scores move only where evidence quality changed.

Important catalysts: next 7–30 days

Sep. 7 · Monday — U.S. Labor Day
U.S. cash closed. Treat holiday futures and volume cautiously; next normal equity session is Tuesday. Nasdaq schedule

Sep. 8 · Tuesday — U.S. cash repricing
First normal opportunity for single-stock confirmations after the tanker strikes. Watch WTI, VIX, rates and opening breadth; do not assume today's futures move predicts every stock.

Sep. 10 · after U.S. close — ORCL and ADBE earnings
Cloud backlog/capacity/capex and AI monetization. Consensus is not guidance. Nasdaq API

Sep. 11 · 14:30 CEST — August U.S. CPI
Duration test; outcome unknown at 08:30 Italy. BLS access was blocked in this run, so no unreleased value is stated. BLS schedule

Sep. 15–16 — FOMC + Summary of Economic Projections
Jobs, CPI, oil and political pressure collide. Official date verified directly. Federal Reserve

Sep. 21 / 30 — AVGO dividend record / payment
$0.65 quarterly cash dividend; a capital-return date, not an operating catalyst. SEC 8-K

Sep. 24 / Sep. 30 — U.S. international transactions / GDP third estimate + August PCE
Later-window growth/inflation checkpoints. BEA schedule

Sep. 29 / 30 — IONQ warrants cease trading / expire
Capital-structure event; common stock continues to trade. SEC 8-K

Focus-theme clinical/FDA/conference check
No specific dated 7–30 day peptide readout, FDA decision or focus-theme conference is promoted because none was established in the primary sources reviewed. NCT05929079 results remain absent. registry

Bottom line by horizon

Day trade · today/Tuesday

Bias: no U.S. cash trade today; capital preservation. Tuesday, wait for the first 30–60 minutes and use only stated VRT/NVDA confirmations.

Biggest risk: escalation or de-escalation gap through levels. Invalidation of cautious bias: WTI loses $91.48, VIX remains below 15.44 and S&P reclaims 7,747.71 with breadth.

1–4 week swing

Bias: risk-off watch/selective; smaller exposure before ORCL/ADBE, CPI and FOMC. Avoid unconfirmed quantum and binary biotech momentum.

Biggest risk: sustained oil shock plus CPI validates tighter policy. Invalidation: de-escalation, S&P close above 7,747.71, VIX below 14 and 2Y below 4.34% restore neutral/selective.

3–12+ month investment

Bias: favor profitable AI infrastructure only after valuation, FCF, debt and concentration review; demand unit-economic proof in quantum and endpoint/safety/runway evidence in biotech.

Biggest risk: persistent oil/high rates plus AI-capex digestion, deal misexecution, dilution or clinical failure. Invalidation: durable order, margin and FCF deterioration—not one holiday session—breaks the structural AI thesis.

Data quality, retrievals and limitations

Session/timestamps: generated Monday 08:34:13 CEST. TradingView fields were retrieved near 08:31 CEST and identified as streaming or delayed 600–900 seconds; CNBC premarket showed 02:23 EDT updates. U.S. cash and thematic stocks are Sep. 4.
Live research completed: successful retrievals included CNBC browser pages (premarket/world/geopolitics), TradingView scanners for 30+ futures, indices, rates and thematic stocks, Treasury XML, Federal Reserve HTML, Nasdaq earnings/holiday data, SEC submissions plus four primary filings, ClinicalTrials.gov API, BEA schedule and Google News RSS discovery.
Cross-checks: CNBC and TradingView agreed closely on ES/NQ/YM; official Treasury confirms 4.37%/4.78%; Nasdaq verifies ORCL/ADBE; Fed verifies Sep. 15–16; SEC verifies NVDA/AVGO/IONQ/NVO events; ClinicalTrials.gov verifies trial design/status and no results.
Access failures/retries: Yahoo chart requests returned HTTP 429 for all queried symbols; Stooq returned JavaScript proof-of-work instead of CSV (and one multi-symbol URL returned 404); FRED timed out; MarketWatch presented a DataDome CAPTCHA. Generic web search/web extraction returned “Payment Required / insufficient credits.” Alternatives above supplied the report. Direct BLS returned HTTP 403; its official link and previously verified schedule are retained, with no release value claimed.
News quality: Google News RSS was used for discovery only; low-authority market articles were not used as evidence. The geopolitical account is attributed to CNBC's report of CENTCOM statements and remains subject to change.
Research discipline: no analyst rating, target, exact borrow availability/fee, or unreleased result is invented. Levels use verified latest OHLC and can gap. No exact valuation multiple is promoted without refreshed enterprise-value normalization.
Biotech/short discipline: trial phase, enrollment, endpoints and results absence are stated; efficacy, safety, cash runway and regulatory timing are not inferred. Short losses can be unlimited and squeezes severe.